Wuhan Hvsen Biotechnology Co Ltd (300871) - Net Assets
Based on the latest financial reports, Wuhan Hvsen Biotechnology Co Ltd (300871) has net assets worth CN¥2.12 Billion CNY (≈ $309.94 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.96 Billion ≈ $432.85 Million USD) and total liabilities (CN¥839.94 Million ≈ $122.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Wuhan Hvsen Biotechnology Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.12 Billion |
| % of Total Assets | 71.6% |
| Annual Growth Rate | 32.45% |
| 5-Year Change | 6.24% |
| 10-Year Change | N/A |
| Growth Volatility | 84.22 |
Wuhan Hvsen Biotechnology Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Wuhan Hvsen Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 300871 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Wuhan Hvsen Biotechnology Co Ltd (2016–2024)
The table below shows the annual net assets of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2024. For live valuation and market cap data, see 300871 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.47 Billion ≈ $214.41 Million |
-2.92% |
| 2023-12-31 | CN¥1.51 Billion ≈ $220.86 Million |
-2.09% |
| 2022-12-31 | CN¥1.54 Billion ≈ $225.56 Million |
-4.78% |
| 2021-12-31 | CN¥1.62 Billion ≈ $236.89 Million |
+17.38% |
| 2020-12-31 | CN¥1.38 Billion ≈ $201.81 Million |
+264.58% |
| 2019-12-31 | CN¥378.28 Million ≈ $55.35 Million |
+16.57% |
| 2018-12-31 | CN¥324.52 Million ≈ $47.49 Million |
+45.45% |
| 2017-12-31 | CN¥223.11 Million ≈ $32.65 Million |
+44.22% |
| 2016-12-31 | CN¥154.70 Million ≈ $22.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Wuhan Hvsen Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1651.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥277.23 Million | 19.02% |
| Common Stock | CN¥165.77 Million | 11.37% |
| Other Components | CN¥1.01 Billion | 69.61% |
| Total Equity | CN¥1.46 Billion | 100.00% |
Wuhan Hvsen Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Wuhan Hvsen Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ferroglobe PLC
NASDAQ:GSM
|
$761.43 Million |
|
OCI NV
AS:OCI
|
$761.80 Million |
|
Gokul Agro Resources Limited
NSE:GOKULAGRO
|
$761.88 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
$762.02 Million |
|
LOGAN GROUP HD -10
F:5LP
|
$761.17 Million |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
$761.07 Million |
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
$760.89 Million |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
$760.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Wuhan Hvsen Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,509,281,062 to 1,457,576,824, a change of -51,704,238 (-3.4%).
- Net loss of 20,155,591 reduced equity.
- Dividend payments of 59,155,946 reduced retained earnings.
- Share repurchases of 3,257,670 reduced equity.
- Other factors increased equity by 30,864,969.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-20.16 Million | -1.38% |
| Dividends Paid | CN¥59.16 Million | -4.06% |
| Share Repurchases | CN¥3.26 Million | -0.22% |
| Other Changes | CN¥30.86 Million | +2.12% |
| Total Change | CN¥- | -3.43% |
Book Value vs Market Value Analysis
This analysis compares Wuhan Hvsen Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.93x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 19.86x to 2.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.29 | CN¥25.71 | x |
| 2017-12-31 | CN¥1.87 | CN¥25.71 | x |
| 2018-12-31 | CN¥2.70 | CN¥25.71 | x |
| 2019-12-31 | CN¥2.28 | CN¥25.71 | x |
| 2020-12-31 | CN¥8.32 | CN¥25.71 | x |
| 2021-12-31 | CN¥9.75 | CN¥25.71 | x |
| 2022-12-31 | CN¥9.32 | CN¥25.71 | x |
| 2023-12-31 | CN¥9.09 | CN¥25.71 | x |
| 2024-12-31 | CN¥8.79 | CN¥25.71 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Wuhan Hvsen Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.68%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 2.07x
- Recent ROE (-1.38%) is below the historical average (14.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 31.95% | 19.17% | 1.01x | 1.65x | CN¥33.95 Million |
| 2017 | 39.63% | 22.12% | 1.16x | 1.54x | CN¥66.11 Million |
| 2018 | 22.00% | 16.92% | 0.90x | 1.44x | CN¥38.95 Million |
| 2019 | 18.18% | 16.10% | 0.66x | 1.72x | CN¥30.94 Million |
| 2020 | 10.89% | 19.31% | 0.44x | 1.27x | CN¥12.24 Million |
| 2021 | 8.21% | 13.34% | 0.36x | 1.69x | CN¥-29.02 Million |
| 2022 | 3.42% | 5.15% | 0.34x | 1.94x | CN¥-101.44 Million |
| 2023 | 1.11% | 1.65% | 0.34x | 1.97x | CN¥-134.15 Million |
| 2024 | -1.38% | -1.68% | 0.40x | 2.07x | CN¥-165.91 Million |
Industry Comparison
This section compares Wuhan Hvsen Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,596,138,595
- Average return on equity (ROE) among peers: 5.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Wuhan Hvsen Biotechnology Co Ltd (300871) | CN¥2.12 Billion | 31.95% | 0.40x | $761.21 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $129.22 Million | 9.00% | 0.43x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $602.14 Million | -32.92% | 2.51x | $1.63 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $605.96 Million | 9.30% | 0.37x | $456.85 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $467.03 Million |
| Chengzhi Shareholding Co Ltd (000990) | $16.70 Billion | 2.13% | 0.46x | $2.00 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.89 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.36 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $5.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $575.82 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $1.93 Billion |
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company offers tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. It produces various vet… Read more